Trexquant Investment LP Has $777,000 Position in Solid Biosciences Inc. (NASDAQ:SLDB)

Trexquant Investment LP lifted its holdings in Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) by 256.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 194,281 shares of the company's stock after acquiring an additional 139,851 shares during the period. Trexquant Investment LP owned approximately 0.49% of Solid Biosciences worth $777,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. China Universal Asset Management Co. Ltd. acquired a new position in shares of Solid Biosciences during the 4th quarter worth approximately $34,000. Sei Investments Co. bought a new stake in shares of Solid Biosciences in the fourth quarter valued at approximately $52,000. The Manufacturers Life Insurance Company acquired a new stake in Solid Biosciences during the third quarter worth approximately $71,000. XTX Topco Ltd acquired a new stake in Solid Biosciences during the third quarter worth approximately $121,000. Finally, Rhumbline Advisers increased its stake in Solid Biosciences by 10.5% during the 4th quarter. Rhumbline Advisers now owns 43,677 shares of the company's stock worth $175,000 after acquiring an additional 4,161 shares during the period. 81.46% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SLDB has been the topic of several analyst reports. HC Wainwright increased their target price on Solid Biosciences from $16.00 to $20.00 and gave the stock a "buy" rating in a report on Monday, March 10th. JPMorgan Chase & Co. reduced their price objective on shares of Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating on the stock in a research note on Thursday, March 13th. Chardan Capital restated a "buy" rating and issued a $16.00 target price on shares of Solid Biosciences in a research report on Friday, March 7th. Finally, Truist Financial started coverage on shares of Solid Biosciences in a research report on Wednesday, January 8th. They set a "buy" rating and a $16.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company's stock. According to MarketBeat, Solid Biosciences has a consensus rating of "Buy" and a consensus target price of $15.67.

Remove Ads

Solid Biosciences Trading Down 0.4 %

Solid Biosciences stock traded down $0.01 during mid-day trading on Tuesday, reaching $2.70. The company had a trading volume of 1,290,164 shares, compared to its average volume of 885,837. The business has a fifty day simple moving average of $4.37 and a 200 day simple moving average of $4.73. The company has a market cap of $209.23 million, a P/E ratio of -0.89 and a beta of 2.07. Solid Biosciences Inc. has a fifty-two week low of $2.48 and a fifty-two week high of $10.99.

Solid Biosciences Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.